Sarcoidosis-Pipeline Review, H1 2016

Sarcoidosis-Pipeline Review, H1 2016


  • Products Id :- GMDHC7796IDB
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Sarcoidosis-Pipeline Review, H1 2016', provides an overview of the Sarcoidosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcoidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcoidosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Sarcoidosis

The report reviews pipeline therapeutics for Sarcoidosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Sarcoidosis therapeutics and enlists all their major and minor projects

The report assesses Sarcoidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Sarcoidosis

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Sarcoidosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sarcoidosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Sarcoidosis Overview 6

Therapeutics Development 7

Pipeline Products for Sarcoidosis-Overview 7

Sarcoidosis-Therapeutics under Development by Companies 8

Sarcoidosis-Pipeline Products Glance 9

Clinical Stage Products 9

Early Stage Products 10

Sarcoidosis-Products under Development by Companies 11

Sarcoidosis-Companies Involved in Therapeutics Development 12

Araim Pharmaceuticals, Inc. 12

FirstString Research, Inc. 13

PharmaIN Corporation 14

Sarcoidosis-Therapeutics Assessment 15

Assessment by Monotherapy Products 15

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Drug Profiles 23

ABS-11-Drug Profile 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

cibinetide-Drug Profile 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

eprodisate disodium-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Synthetic Peptide for Sarcoidosis-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Sarcoidosis-Recent Pipeline Updates 32

Sarcoidosis-Dormant Projects 35

Sarcoidosis-Discontinued Products 36

Sarcoidosis-Product Development Milestones 37

Featured News & Press Releases 37

Aug 12, 2015: BELLUS Health narrows timelines for the Phase III study for KIACTA 37

Oct 28, 2014: Araim Pharmaceuticals Given FDA Fast Track Designation to ARA 290 for the Treatment of Sarcoidosis-associated Small Fiber Neuropathy 38

Sep 19, 2014: Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta Using Crowdsourcing And Telemonitoring 39

Oct 10, 2013: Araim Pharmaceuticals' ARA 290, a Peptide Engineered to Activate Innate Repair, Receives Orphan Drug Designation from the European Commission 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Figures

Number of Products under Development for Sarcoidosis, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Comparative Analysis by Clinical Stage Development, H1 2016 9

Assessment by Monotherapy Products, H1 2016 15

Number of Products by Targets, H1 2016 16

Number of Products by Stage and Targets, H1 2016 16

Number of Products by Routes of Administration, H1 2016 19

Number of Products by Stage and Routes of Administration, H1 2016 19

Number of Products by Molecule Types, H1 2016 21

Number of Products by Stage and Molecule Types, H1 2016 21

List of Tables

Number of Products under Development for Sarcoidosis, H1 2016 7

Number of Products under Development by Companies, H1 2016 8

Comparative Analysis by Clinical Stage Development, H1 2016 9

Comparative Analysis by Early Stage Development, H1 2016 10

Products under Development by Companies, H1 2016 11

Sarcoidosis-Pipeline by Araim Pharmaceuticals, Inc., H1 2016 12

Sarcoidosis-Pipeline by FirstString Research, Inc., H1 2016 13

Sarcoidosis-Pipeline by PharmaIN Corporation, H1 2016 14

Assessment by Monotherapy Products, H1 2016 15

Number of Products by Stage and Target, H1 2016 17

Number of Products by Stage and Mechanism of Action, H1 2016 18

Number of Products by Stage and Route of Administration, H1 2016 20

Number of Products by Stage and Molecule Type, H1 2016 22

Sarcoidosis Therapeutics-Recent Pipeline Updates, H1 2016 32

Sarcoidosis-Dormant Projects, H1 2016 35

Sarcoidosis-Discontinued Products, H1 2016 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Araim Pharmaceuticals, Inc.

FirstString Research, Inc.

PharmaIN Corporation

Sarcoidosis Therapeutic Products under Development, Key Players in Sarcoidosis Therapeutics, Sarcoidosis Pipeline Overview, Sarcoidosis Pipeline, Sarcoidosis Pipeline Assessment

select a license

Single User License
USD 2000 INR 128700
Site License
USD 4000 INR 257400
Corporate User License
USD 6000 INR 386100

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com